スウェーデン医薬品庁と薬事規制に関する守秘取り決めを締結しました ｜報道発表資料｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000170062.htmlThe evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
スウェーデン医薬品庁と薬事規制に関する守秘取り決めを締結しました ｜報道発表資料｜厚生労働省
Open the archived HTML with saved-time metadata attached.
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
This page is a press release from Japan's Ministry of Health, Labour and Welfare dated July 4, 2017. It announces that Japan's MHLW and the Pharmaceuticals and Medical Devices Agency (PMDA) concluded a confidentiality agreement on pharmaceutical regulations with Sweden's Medical Products Agency (MPA) on June 28, 2017. The agreement aims to promote access to safe, effective, and high-quality products and facilitate information sharing between the two countries. It is expected to enhance the exchange of information on innovative drug development and post-market safety measures. The agreement aligns with Japan's International Pharmaceutical Regulatory Harmonization Strategy established in 2015.
